SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CUBIST PHARMACEUTICALS (CBST) -- Ignore unavailable to you. Want to Upgrade?

To: idos who wrote (235)11/23/2008 8:24:23 AM
From: telephonics  Read Replies (2) | Respond to of 252
 
FDA decision based upon data which shows it works as well as vancomycin but says nothing about its effectiveness as compared to Cubicin.Had they made that comparison they would have reached a different conclusion.



To: idos who wrote (235)11/28/2008 7:43:48 AM
From: idos  Read Replies (1) | Respond to of 252
 
Late last week, iclaprim got a negative panel opinion and a couple of days ago, ceftobiprole got a Complete Response Letter, both for the treatment of cSSSI. Good for CBST.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News